RxDoctor Payments Data

Steven Blumlein, MD

Cardiovascular Disease · San Francisco, CANPI 1568473361

Payments from drug & device makers

$882in general payments, 2019–2025

Across 43 payments — averaging $20.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$157
  • Amgen$100
  • Regeneron Healthcare Solutions, Inc.$96
  • Astellas Pharma US Inc$93
  • Novartis$78
  • Johnson & Johnson$76
  • plus $282 from 9 others

What the payments were for

  • Food & beverage$87099%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$882 in reported general payments places this provider in the 30th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$299,935
Medicare patients
1,432
Services billed
3,524

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban535$611,485
OpsumitMacitentan22$259,216
XareltoRivaroxaban112$157,338
EntrestoSacubitril/Valsartan64$73,102
Repatha SureclickEvolocumab49$51,817
PancreazeLipase/Protease/Amylase11$35,802
JardianceEmpagliflozin22$25,650
Praluent PenAlirocumab29$20,968
Atorvastatin Calcium604$6,867
Metoprolol Succinate373$6,186
Diltiazem 24hr Er (Cd)Diltiazem Hcl106$4,405
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide176$4,055
Ezetimibe127$3,629
Amlodipine Besylate457$3,466
Carvedilol210$3,239

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Opsumit$22$259,21622 claims
Johnson & JohnsonXarelto$76$157,338112 claims
NovartisEntresto$78$73,10264 claims
Boehringer IngelheimJardiance$21$25,65022 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →